I-Mab (IMAB) CEO Joan Huaqiong Shen on Q2 2021 Results - Earnings Call Transcript

I-Mab (NASDAQ:IMAB) Q2 2021 Earnings Conference Call August 31, 2021 8:00 AM ET

Company Participants

Jingwu Zhang Zang - Founder, Chairman and Director
Joan Huaqiong Shen - CEO
Jielun Zhu - CFO

Conference Call Participants

Kelly Shi - Jefferies
Jennifer Kim - Cantor Fitzgerald
Joseph Catanzaro - Piper Sandler & Co.

Jielun Zhu

Thank you, everyone, thank you for standing by. And welcome to I-MAb 2021 Interim Business Update and the Financial Results Conference Call. Earlier today, we issued a press release detailing I-Mab's significant pipeline progress and the corporate highlights during the first half of 2021 and upcoming milestones for the rest of 2021, as well as a review of our financial results for the first six months in 2021. The press release can be accessed on the Investor portion of our website.

Joining me today on the call from I-MAb's senior management team are Dr. Jingwu Zang, our Founder, Chairman and Director and Dr. Joan Shen, our Chief Executive Officer. Dr. Zang will provide a high level overview of our recent achievements and the strategy going forward. He will then highlight the progress we have made in our key clinical programs and upcoming milestones and catalysts. Dr. Shen will then comment on the status of other important clinical assets and corporate achievements. I will then provide a brief summary of our financial results and our preparation for the dual listings in Greater China before we take questions from the audience for Q&A.

Now without much ado, I will turn the call over to Dr. Zang, our Founder for - to start the call. Dr. Zang?

Jingwu Zhang Zang

Thank you, Jielun. Thank you all for joining the call today.

We are very excited to report to you the remarkable progress that company has made since the beginning of